Antibiotic-resistant bacteria, which are growing at a frightening rate worldwide, has put the world on a long-standing alert. The COVID-19 health crisis reinforced the pressing need to address a fast-developing pandemic. To mitigate these health emergencies and prevent economic collapse, cheap, practical, and easily applicable infection control techniques are essential worldwide. Application of light in the form of photodynamic action on microorganisms and viruses has been growing and is now successfully applied in several areas. The efficacy of this approach has been demonstrated in the fight against viruses, prompting additional efforts to advance the technique, including safety use protocols. In particular, its application to suppress respiratory tract infections and to provide decontamination of fluids, such as blood plasma and others, can become an inexpensive alternative strategy in the fight against viral and bacterial infections. Diverse early treatment methods based on photodynamic action enable an accelerated response to emerging threats prior to the availability of preventative drugs. In this review, we evaluate a vast number of photodynamic demonstrations and first-principle proofs carried out on viral control, revealing its potential and encouraging its rapid development toward safe clinical practice. This review highlights the main research trends and, as a futuristic exercise, anticipates potential situations where photodynamic treatment can provide a readily available solution.
References
1.
B. K.
Tischer
and N.
Osterrieder
, “Herpesviruses—A zoonotic threat?
,” Vet. Microbiol.
140
, 266
–270
(2010
).2.
K. K.
Irwin
, N.
Renzette
, T. F.
Kowalik
, and J. D.
Jensen
, “Antiviral drug resistance as an adaptive process
,” Virus Evol.
2
, vew014
(2016
).3.
D. W.
Kimberlin
and R. J.
Whitley
, “Antiviral resistance: Mechanisms, clinical significance, and future implications
,” J. Antimicrob. Chemother.
37
, 403
–421
(1996
).4.
K. I.
Moller
, B.
Kongshoj
, P. A.
Philipsen
, V. O.
Thomsen
, and C.
Wulf
, “How Finsen's light cured lupus vulgaris
,” Photodermatology
21
, 118
–124
(2005
).5.
E.
Hideg
, M. A. K.
Jansen
, and A.
Strid
, “UV-B exposure, ROS, and stress: Inseparable companions or loosely linked associates?
,” Trends Plant Sci.
18
, 107
–115
(2013
).6.
S.-W. D.
Tsen
, “A novel ultrashort pulsed laser method pathogen inactivation
,” Ph.D. dissertation (Washington University
, 2016
).7.
A.
Berchtikou
, A. A.
Greschner
, P.
Tijssen
, M. A.
Gauthier
, and T.
Ozaki
, “Accelerated inactivation of M13 bacteriophage using millijoule femtosecond lasers
,” J. Biophotonics
13
, e201900001
(2020
).8.
E.
Sotiriou
, T.
Koussidou-Eremonti
, G.
Chaidemenos
, Z.
Apalla
, and D.
Ioannides
, “Photodynamic therapy for distal and lateral subungual toenail onychomycosis caused by Trichophyton rubrum: Preliminary results of a single-centre open trial
,” Acta Derm. Venereol.
90
, 216
–217
(2010
).9.
P.
Hillemanns
, M. H.
Einstein
, and O. E.
Iversen
, “Topical hexaminolevulinate photodynamic therapy for the treatment of persistent human papilloma virus infections and cervical intraepithelial neoplasia
,” Expert Opin. Investig. Drugs
24
, 273
–281
(2015
).10.
P.
Soergel
, G. F.
Dahl
, M.
Onsrud
, and P.
Hillemanns
, “Photodynamic therapy of cervical intraepithelial neoplasia 1-3 and HPV infection with methylaminolevulinate and hexaminolevulinate—A double-blind, dose-finding study
,” Lasers Surg. Med.
44
, 468
–474
(2012
).11.
K.
Moghissi
, K.
Dixon
, J. A. C.
Thorpe
, M.
Stringer
, and C.
Oxtoby
, “Photodynamic therapy (PDT) in early central lung cancer: A treatment option for patients ineligible for surgical resection
,” Thorax
62
, 391
–395
(2007
).12.
A. C. E.
Moor
, A.
van der Veen
, T. M. A. R.
Dubbelman
, J.
VanSteveninck
, and A.
Brand
, “Photodynamic sterilization of red cells and its effect on contaminating white cells: Viability and mechanism of cell death
,” Transfusion
39
, 599
–607
(1999
).13.
S.
Rywkin
, et al., “New phthalocyanines for photodynamic virus inactivation in red blood cell concentrates
,” Photochem. Photobiol.
60
, 165
–170
(1994
).14.
J.
Wang
et al., “Bacterial species-identifiable magnetic nanosystems for early sepsis diagnosis and extracorporeal photodynamic blood disinfection
,” Nanoscale
10
, 132
–141
(2018
).15.
M. C.
Geralde
et al., “Pneumonia treatment by photodynamic therapy with extracorporeal illumination—An experimental model
,” Physiol. Rep.
5
, 1
–7
(2017
).16.
M. N.
Mead
, “Benefits of sunlight: A bright spot for human health
,” Environ. Health Perspect.
116
, 160
–167
(2008
).17.
M. J.
Garland
, C. M.
Cassidy
, D.
Woolfson
, and R. F.
Donnelly
, “Designing photosensitizers for photodynamic therapy: Strategies, challenges and promising developments
,” Future Medicin. Chem.
1
, 667
–691
(2009
).18.
P. C.
Lo
et al., “New amphiphilic silicon(IV) phthalocyanines as efficient photosensitizers for photodynamic therapy: Synthesis, photophysical properties, and in vitro photodynamic activities
,” Chem. - A Eur. J.
10
, 4831
–4838
(2004
).19.
W.
Randazzo
, R.
Aznar
, and G.
Sánchez
, “Curcumin-mediated photodynamic inactivation of norovirus surrogates
,” Food Environ. Virol.
8
, 244
–250
(2016
).20.
A. M.
Prince
, et al., “Strategies for evaluation of enveloped virus inactivation in red cell concentrates using hypericin
,” Photochem. Photobiol.
71
, 188
–195
(2000
).21.
M. E.
Lim
, Y.-l.
Lee
, Y.
Zhang
, and J. J. H.
Chu
, “Photodynamic inactivation of viruses using upconversion nanoparticles
,” Biomaterials
33
, 1912
–1920
(2012
).22.
M. J.
Shikowitz
et al., “Clinical trial of photodynamic therapy with meso-tetra (Hydroxyphenyl) chlorin for respiratory papillomatosis
,” Arch. Otolaryngol. - Head Neck Surg.
131
, 99
–105
(2005
).23.
S.
Cui
et al., “In vivo targeted deep-tissue photodynamic therapy based on near-infrared light triggered upconversion nanoconstruct
,” ACS Nano
7
, 676
–688
(2013
).24.
J.
D'Orazio
, S.
Jarrett
, A.
Amaro-Ortiz
, and T.
Scott
, “UV radiation and the skin
,” Int. J. Mol. Sci.
14
, 12222
–12248
(2013
).25.
A.
Scrima
et al., “Structural basis of UV DNA-damage recognition by the DDB1-DDB2 complex
,” Cell
135
, 1213
–1223
(2008
).26.
S. W. D.
Tsen
, T. C.
Wu
, J. G.
Kiang
, and K. T.
Tsen
, “Prospects for a novel ultrashort pulsed laser technology for pathogen inactivation
,” J. Biomed. Sci.
19
, 1
(2012
).27.
J. C.
Wiggle
et al., “No effect of femtosecond laser pulses on M13, E. coli, DNA, or protein
,” J. Biomed. Opt.
19
, 115008
(2014
).28.
L.
Pan
, J.
Liu
, and J.
Shi
, “Intranuclear photosensitizer delivery and photosensitization for enhanced photodynamic therapy with ultralow irradiance
,” Adv. Funct. Mater.
24
, 7318
–7327
(2014
).29.
J.
Moan
, “On the diffusion length of singlet oxygen in cells and tissues
,” J. Photochem. Photobiol.
6
, 343
–347
(1990
).30.
D. G.
Meckes
and N.
Raab-traub
, “Microvesicles and viral infection
,” J. Virol.
85
, 12844
–12854
(2011
).31.
S. N.
Morris
, A. N.
Fader
, M. P.
Milad
, and H. J.
Dionisi
, “Understanding the ‘scope’ of the problem: Why laparoscopy is considered safe during the COVID-19 pandemic
,” J. Minim. Invasive Gynecol.
27
, 789
–791
(2020
).32.
M. E.
Fabry
et al., “Some aspects of the pathophysiology of homozygous Hb CC erythrocytes
,” J. Clin. Invest.
67
, 1284
–1291
(1981
).33.
D. A.
Guertin
and D. M.
Sabatini
, “Cell size control
,” in Encyclopedia of Life Sciences
(John Wiley & Sons, Ltd.
, Chichester, UK
). 34.
M.
Wainwright
, “Local treatment of viral disease using photodynamic therapy
,” Int. J. Antimicrob. Agents
21
, 510
–520
(2003
).35.
P. R.
Ogilby
, “Singlet oxygen: There is indeed something new under the sun
,” Chem. Soc. Rev.
39
, 3181
–3209
(2010
).36.
J.
Lenard
, A.
Rabson
, and R.
Vanderoef
, “Photodynamic inactivation of infectivity of human immunodeficiency virus and other enveloped viruses using hypericin and rose bengal: Inhibition of fusion and syncytia formation
,” Proc. Natl. Acad. Sci.
90
, 158
–162
(1993
).37.
A.
Wiehe
, J. M.
O'Brien
, and M. O.
Senge
, “Trends and targets in antiviral phototherapy
,” Photochem. Photobiol. Sci.
18
, 2565
–2612
(2019
).38.
K.
Zhu
, G.
Liu
, J.
Hu
, and S.
Liu
, “Near-infrared light-activated photochemical internalization of reduction-responsive polyprodrug vesicles for synergistic photodynamic therapy and chemotherapy
,” Biomacromolecules
18
, 2571
–2582
(2017
).39.
L.
Costa
et al., “Susceptibility of non-enveloped DNA- and RNA-type viruses to photodynamic inactivation
,” Photochem. Photobiol. Sci.
11
, 1520
–1523
(2012
).40.
M. D.
Weitzman
and A.
Fradet-Turcotte
, “Virus DNA replication and the host DNA damage response
,” Annu. Rev. Virol.
5
, 141
–164
(2018
).41.
M.
Hossain
and G. S.
Kumar
, “DNA intercalation of methylene blue and quinacrine: New insights into base and sequence specificity from structural and thermodynamic studies with polynucleotides
,” Mol. Biosyst.
5
, 1311
–1322
(2009
).42.
F. A.
Jalilian
, “Effect of photodynamic therapy by 810 and 940 nm diode laser on Herpes Simplex Virus 1: An in vitro study
,” Photodiagnosis Photodyn. Ther.
25
, 87
–91
(2019
).43.
A. B.
Ormond
and H. S.
Freeman
, “Dye sensitizers for photodynamic therapy
,” Materials
6
, 817
–840
(2013
).44.
J.
Dairou
, C.
Vever-Bizet
, and D.
Brault
, “Interaction of sulfonated anionic porphyrins with HIV glycoprotein gp120: Photodamages revealed by inhibition of antibody binding to V3 and C5 domains
,” Antiviral Res.
61
, 37
–47
(2004
).45.
Z.
Smetana
et al., “Photodynamic inactivation of herpes viruses with phthalocyanine derivatives
,” J. Photochem. Photobiol.
22
, 37
–43
(1994
).46.
A.
Ohtsuki
, T.
Hasegawa
, Y.
Hirasawa
, H.
Tsuchihashi
, and S.
Ikeda
, “Photodynamic therapy using light-emitting diodes for the treatment of viral warts
,” J. Dermatol.
36
, 525
–528
(2009
).47.
H.
Majiya
, O. O.
Adeyemi
, N. J.
Stonehouse
, and P.
Millner
, “Photodynamic inactivation of bacteriophage MS2: The A-protein is the target of virus inactivation
,” J. Photochem. Photobiol.
178
, 404
–411
(2017
).48.
K. L.
Warfield
et al., “Ebola virus inactivation with preservation of antigenic and structural integrity by a photoinducible alkylating agent
,” J. Infect. Dis.
196
, S276
–S283
(2007
).49.
M. R.
Ke
et al., “Oligolysine-conjugated zinc(II) phthalocyanines as efficient photosensitizers for antimicrobial photodynamic therapy
,” Chem. - An Asian J.
9
, 1868
–1875
(2014
).50.
M. L.
Embleton
, S. P.
Nair
, B. D.
Cookson
, and M.
Wilson
, “Antibody-directed photodynamic therapy of methicillin-resistant Staphylococcus aureus
,” Microb. Drug Resist.
10
, 92
–97
(2004
).51.
S.
Wang
et al. “Indocyanine green as effective antibody conjugate for intracellular molecular targeted photodynamic therapy
,” J. Biomed. Opt.
21
, 078001
(2016
).52.
M.
Sadraeian
et al., “Photoimmunotherapy using cationic and anionic photosensitizer-antibody conjugates against HIV Env-expressing cells
,” Int. J. Mol. Sci.
21
, 9151
(2020
).53.
Y.
Raviv
et al., “Hydrophobic inactivation of influenza viruses confers preservation of viral structure with enhanced immunogenicity
,” J. Virol.
82
, 4612
–4619
(2008
).54.
M. A.
Tortorici
et al., “Structural basis for human coronavirus attachment to sialic acid receptors
,” Nat. Struct. Mol. Biol.
26
, 481
–489
(2019
).55.
P. M. R.
Pereira
et al., “Antibodies armed with photosensitizers: From chemical synthesis to photobiological applications
,” Org. Biomol. Chem.
13
, 2518
–2529
(2015
).56.
Z.
Li
et al., “Existing drugs as broad-spectrum and potent inhibitors for Zika virus by targeting NS2B-NS3 interaction
,” Cell Res.
27
, 1046
–1064
(2017
).57.
R. M.
Gulick
et al., “Phase I studies of hypericin, the active compound in St. John's wort, as an antiretroviral agent in HIV-infected adults: AIDS clinical trials group protocols 150 and 258
,” Ann. Intern. Med.
130
, 510
–514
(1999
).58.
S.
Onoue
et al., “In vitro photochemical and phototoxicological characterization of major constituents in St. John's wort (Hypericum perforatum) extracts
,” Phytochemistry
72
, 1814
–1820
(2011
).59.
J. B.
Hudson
, L.
Harris
, and G. H. N.
Towers
, “The importance of light in the anti-HIV effect of hypericin
,” Antiviral Res.
20
, 173
–178
(1993
).60.
J. B.
Hudson
et al., “Further investigations on the antiviral activities of medicinal plants of Togo
,” Pharm. Biol.
38
, 46
–50
(2000
).61.
J. B.
Hudson
, M. K.
Lee
, B.
Sener
, and N.
Erdemoglu
, “Antiviral activities in extracts of Turkish medicinal plants
,” Pharm. Biol.
38
, 171
–175
(2000
).62.
L. R.
Comini
et al., “Antimicrobial activity of anthraquinone derivatives from Heterophyllaea pustulata (Rubiaceae)
,” J. Photochem. Photobiol. B
102
, 108
–114
(2011
).63.
J. M.
Jacobson
et al., “Pharmacokinetics, safety, and antiviral effects of hypericin, a derivative of St. John's wort plant, in patients with chronic hepatitis C virus infection
.,” Antimicrob. Agents Chemother.
45
, 517
–524
(2001
).64.
M.
Blank
et al., “Antimetastatic activity of the photodynamic agent hypericin in the dark
,” Int. J. Cancer
111
, 596
–603
(2004
).65.
J.
Montanari
et al., “Sunlight triggered photodynamic ultradeformable liposomes against Leishmania braziliensis are also leishmanicidal in the dark
,” J. Controlled Release
147
, 368
–376
(2010
).66.
L. G.
Sabino
et al., “Experimental evidence and model explanation for cell population characteristics modification when applying sequential photodynamic therapy
,” Laser Phys. Lett.
8
, 239
–246
(2011
).67.
I. O. L.
Bacellar
, T. M.
Tsubone
, C.
Pavani
, and M. S.
Baptista
, “Photodynamic efficiency: From molecular photochemistry to cell death
,” Int. J. Mol. Sci.
16
, 20523
–20559
(2015
).68.
M. R.
Hamblin
and T.
Hasan
, “Photodynamic therapy: A new antimicrobial approach to infectious disease?
,” Photochem. Photobiolog. Sci.
3
, 436
–450
(2004
).69.
B.
Muz
, P.
de la Puente
, F.
Azab
, and A. K.
Azab
, “The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy
,” Hypoxia
3
, 83
–92
(2015
).70.
V. N.
Nguyen
et al., “An emerging molecular design approach to heavy-atom-free photosensitizers for enhanced photodynamic therapy under hypoxia
,” J. Am. Chem. Soc.
141
, 16243
–16248
(2019
).71.
E.
Delaey
, A.
Vandenbogaerde
, W.
Merlevede
, and P.
De Witte
, “Photocytotoxicity of hypericin in normoxic and hypoxic conditions
,” J. Photochem. Photobiol. B Biol.
56
, 19
–24
(2000
).72.
A. C.
Zangirolami
, N. M.
Inada
, V. S.
Bagnato
, and K. C.
Blanco
, “Biofilm destruction on endotracheal tubes by photodynamic inactivation
,” Infect. Disord. - Drug Targets
18
, 218
–223
(2018
).73.
J. M.
Soares
, T. Q.
Corrêa
, N. M.
Inada
, V. S.
Bagnato
, and K. C.
Blanco
, “In vitro study of photodynamic therapy for treatment of bacteremia in whole blood
,” J. Pharm. Pharmacol.
6
, 863
–869
(2018
).74.
J. M.
Soares
, N. M.
Inada
, V. S.
Bagnato
, and K. C.
Blanco
, “Evolution of surviving Streptoccocus pyogenes from pharyngotonsillitis patients submit to multiple cycles of antimicrobial photodynamic therapy
,” J. Photochem. Photobiol. B Biol.
210
, 111985
(2020
).75.
C. M. G.
de Faria
, N. M.
Inada
, J. D.
Vollet-Filho
, and V. S.
Bagnato
, “A threshold dose distribution approach for the study of PDT resistance development: A threshold distribution approach for the study of PDT resistance
,” J. Photochem. Photobiol. B Biol.
182
, 85
–91
(2018
).76.
J. S. M.
Giusti
et al., “Antimicrobial photodynamic action on dentin using a light-emitting diode light source
,” Photomed. Laser Surg.
26
, 281
–287
(2008
).77.
Yang
, Y.-l.
et al., “Off-label photodynamic therapy for recalcitrant facial flat warts using topical 5-aminolevulinic acid
,” Lasers Med. Sci.
31
, 929
–936
(2016
).78.
L.
Wu
et al., “Efficacy of the combination of superficial shaving with photodynamic therapy for recalcitrant periungual warts
,” Photodiagnosis Photodyn. Ther.
27
, 340
–344
(2019
).79.
Q.
Li
et al., “Comparative study of photodynamic therapy with 5%, 10% and 20% aminolevulinic acid in the treatment of generalized recalcitrant facial verruca plana: A randomized clinical trial
,” J. Eur. Acad. Dermatology Venereol.
28
, 1821
–1826
(2014
).80.
M.
Caucanas
, P.
Gillard
, and O.
Vanhooteghem
, “Efficiency of photodynamic therapy in the treatment of diffuse facial viral warts in an immunosuppressed patient: Towards a gold standard?
,” Case Rep. Dermatol.
2
, 207
–213
(2010
).81.
Z.
Hu
et al., “Dynamics of HPV viral loads reflect the treatment effect of photodynamic therapy in genital warts
,” Photodiagnosis Photodyn. Ther.
21
, 86
–90
(2018
).82.
V.
Nucci
, D.
Torchia
, and P.
Cappugi
, “Treatment of anogenital condylomata acuminata with topical photodynamic therapy: Report of 14 cases and review
,” Int. J. Infect. Dis.
145
, 280
–282
(2010
).83.
H.
Wang
et al., “Treatment of HPV infection-associated cervical condylomata acuminata with 5-aminolevulinic acid-mediated photodynamic therapy
,” Photochem. Photobiol.
88
, 565
–569
(2012
).84.
F. M.
Carbinatto
et al., “Photodynamic therapy of Cervical Intraepithelial Neoplasia (CIN) high grade
,” in Proceedings of Photonic Therapeutics and Diagnostics XII
, 9689, 968948
(SPIE
, San Francisco
, 2016
).85.
J.
Xu
et al., “The combination treatment using CO2 laser and photodynamic therapy for HIV seropositive men with intraanal warts
,” Photodiagnosis Photodyn. Ther.
10
, 186
–193
(2013
).86.
N. M.
Inada
et al., “Photodiagnosis and treatment of condyloma acuminatum using 5-aminolevulinic acid and homemade devices
,” Photodiagnosis Photodyn. Ther.
9
, 60
–68
(2012
).87.
F.
Liang
et al., “Topical 5-aminolevulinic acid photodynamic therapy for laryngeal papillomatosistosis treatment
,” Photodiagnosis Photodyn. Ther.
28
, 136
–141
(2019
).88.
C.
Zhou
et al., “Coblation plus photodynamic therapy (PDT) for the treatment of juvenile onset laryngeal papillomatosis: Case reports
,” World J. Surg. Oncol.
12
, 1
–6
(2014
).89.
S.
Lu
, Y.
Liu
, R.
Shi
, and P.
Zhou
, “Successful treatment of adult-onset recurrent respiratory papillomatosis with CO2 laser and photodynamic therapy
,” Case Rep. Otolaryngol.
2019
, 7394879
.90.
S.
Yang
et al., “Efficacy of microsurgery in combined with topical-PDT in treating recurrent respiratory papillomatosis: Compare JORRP with AORRP
,” Acta Oto-Laryngol.
139
, 1133
–1139
(2019
).91.
S.
Teitelbaum
, L. H.
Azevedo
, and W. E.
Bernaola-Paredes
, “Antimicrobial photodynamic therapy used as first choice to treat herpes zoster virus infection in younger patient: A case report
,” Photobiomodulation, Photomedicine, Laser Surg.
38
, 232
–236
(2020
).92.
B. J.
Osiecka
, P.
Nockowski
, S.
Kwiatkowski
, and J. C.
Szepietowski
, “Photodynamic therapy with red light and 5-aminolaevulinic acid for herpes simplex recurrence: Preliminary results
,” Acta Derm. Venereol.
97
, 1239
–1240
(2017
).93.
J.
Marotti
et al., “High-intensity laser and photodynamic therapy as a treatment for recurrent herpes labialis
,” Photomed. Laser Surg.
28
, 439
–444
(2010
).94.
S.
Nobbe
, R. M.
Trüeb
, L. E.
French
, and G. F. L.
Hofbauer
, “Herpes simplex virus reactivation as a complication of photodynamic therapy
,” Photodermatol. Photoimmunol. Photomed.
27
, 51
–52
(2011
).95.
M.
Galasso
et al., “Inactivating hepatitis C virus in donor lungs using light therapies during normothermic ex vivo lung perfusion
,” Nat. Commun.
10
, 1
–12
(2019
).96.
M.
Perlin
, J. C. H.
Mao
, E. R.
Otis
, N. L.
Shipkowitz
, and R. G.
Duff
, “Photodynamic inactivation of influenza and herpes viruses by hematoporphyrin
,” Antiviral Res.
7
, 43
–51
(1987
).97.
H.
Yin
et al., “Preliminary safety evaluation of photodynamic therapy for blood purification: An animal study
,” Artif. Organs
38
, 510
–515
(2014
).98.
M. A.
Namvar
et al., “Effect of photodynamic therapy by 810 and 940 nm diode laser on Herpes Simplex Virus 1: An in vitro study
,” Photodiagnosis Photodyn. Ther.
25
, 87
–91
(2019
).99.
V. V.
Zverev
et al., “In vitro studies of the antiherpetic effect of photodynamic therapy
,” Lasers Med. Sci.
31
, 849
–855
(2016
).100.
Z. B.
Kvacheva
et al., “Photodynamic inhibition of infection caused by drug-resistant variants of herpes simplex virus type I
,” Bull. Exp. Biol. Med.
135
, 450
–454
(2003
).101.
B. H.
Mahmoud
, C. L.
Hexsel
, I. H.
Hamzavi
, and H. W.
Lim
, “Effects of visible light on the skin
,” Photochem. Photobiol.
84
, 450
–462
(2008
).102.
S. R.
Tsai
and M. R.
Hamblin
, “Biological effects and medical applications of infrared radiation
,” J. Photochem. Photobiol. B Biol.
170
, 197
–207
(2017
).103.
M.
Rehan Zaheer
et al., “Molecular mechanisms of drug photodegradation and photosensitization
,” Curr. Pharm. Des.
22
, 768
–782
(2016
).104.
S.
Onoue
et al., “Chemical photoallergy: Photobiochemical mechanisms, classification, and risk assessments
,” J. Dermatol. Sci.
85
, 4
–11
(2017
).105.
J.
Webber
, D.
Kessel
, and D.
Fromm
, “Side effects and photosensitization of human tissues after aminolevulinic acid
,” J. Surg. Res.
68
, 31
–37
(1997
).106.
M.
Wachowska
et al., “Aminolevulinic acid (ALA) as a prodrug in photodynamic therapy of cancer
,” Molecules
16
, 4140
–4164
(2011
).107.
G. B.
Kharkwal
, S. K.
Sharma
, Y.
Huang
, T.
Dai
, and M. R.
Hamblin
, “Photodynamic therapy for infections: Clinical applications
,” Lasers Surg. Med.
43
, 755
–767
(2011
).108.
M. A.
Lotufo
et al., “Efficacy of photodynamic therapy on the treatment of herpes labialis: A systematic review
,” Photodiagnosis Photodyn. Ther.
29
, 1
–7
(2020
).109.
S.
Radakovic
and A.
Tanew
, “5-aminolaevulinic acid patch-photodynamic therapy in the treatment of actinic cheilitis
,” Photodermatol. Photoimmunol. Photomed.
33
, 306
–310
(2017
).110.
S. H.
Ibbotson
, “Adverse effects of topical photodynamic therapy
,” Photodermatol. Photoimmunol. Photomed.
27
, 116
–130
(2011
).111.
R. W.
Johnson
and R. H.
Dworkin
, “Treatment of herpes zoster and postherpetic neuralgia
,” BMJ
326
, 748
–750
(2003
).112.
I. U.
Park
, C.
Introcaso
, and E. F.
Dunne
, “Human papillomavirus and genital warts: A review of the evidence for the 2015 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines
,” Clin. Infect. Dis.
61
, 849
–855
(2015
).113.
J. M.
Crow
, “HPV: The global burden
,” Nature
488
, S2
–S3
(2012
).114.
115.
E.
Mulhem
and S.
Pinelis
, “Treatment of nongenital cutaneous warts
,” Am. Fam. Physician
84
, 288
–293
(2011
). PMID: 21842775.116.
Y.
Lu
, J.
Wu
, Y.
He
, H.
Yang
, and Y.
Yang
, “Efficacy of topical aminolevulinic acid photodynamic therapy for the treatment of verruca planae
,” Photomed. Laser Surg.
28
, 561
–563
(2010
).117.
J. N. B.
Bavinck
and R. J. M.
Berkhout
, “HPV infections and immunosuppression
,” Clin. Dermatol.
15
, 427
–437
(1997
).118.
H.
De Vuyst
, F.
Lillo
, N.
Broutet
, and J. S.
Smith
, “HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy
,” Eur. J. Cancer Prev.
17
, 545
–554
(2008
).119.
C.
O'Mahony
, “Genital warts: Current and future management options
,” Am. J. Clin. Dermatol.
6
, 239
–243
(2005
).120.
H.
Wang
, X.
Wang
, L.
Zhang
, M.
Guo
, and Z.
Huang
, “Aminolevulinic acid (ALA)-assisted photodynamic diagnosis of subclinical and latent HPV infection of external genital region
,” Photodiagnosis Photodyn. Ther.
5
, 251
–255
(2008
).121.
N. M.
Inada
et al., “Optical techniques for the diagnosis and treatment of lesions induced by the human papillomavirus—A resource letter
,” Photodiagnosis Photodyn. Ther.
23
, 106
–110
(2018
).122.
N.
Inada
et al., “Protoporphyrin IX production and photobleaching during treatment of condyloma by HPV with methyl aminolevulinate
,” Photodiagnosis Photodyn. Ther.
8
, 216
–217
(2011
).123.
N. M.
Inada
et al., “Treatment of vulvar/vaginal condyloma by HPV: Developed instrumentation and clinical report
,” in Proceedings of Photodynamic Therapy: Back to the Future
7380
, 738054
(2009
).124.
M.
Carifi
, D.
Napolitano
, M.
Morandi
, and D.
Dall'Olio
, “Recurrent respiratory papillomatosis: Current and future perspectives
,” Ther. Clin. Risk Manag.
11
, 731
–738
(2015
). 125.
G. D.
Souza
et al., “Oral Human Papillomavirus (HPV) infection in HPV-positive patients with oropharyngeal cancer and their partners
,” J. Clin. Oncol.
32
, 2408
–2416
(2014
).126.
D. S.
Michaud
et al., “High-risk HPV types and head and neck cancer
,” Int. J. Cancer
135
, 1653
–1661
(2014
).127.
M. J.
Silverberg
, P.
Thorsen
, H.
Lindeberg
, L. A.
Grant
, and K. V.
Shah
, “Condyloma in pregnancy is strongly predictive of juvenile-onset recurrent respiratory papillomatosis
,” Obstet. Gynecol.
101
, 645
–652
(2003
).128.
M.
James
, D.
Katundu
, D.
Chussi
, and P.
Shija
, “Prevalence, clinical presentations, associated risk factors and recurrence of laryngeal papillomatosis among inpatients attended at a Tertiary Hospital in Northern zone Tanzania
,” Pan Afr. Med. J.
16
, 209
(2018
).129.
S.
Mallidi
et al., “Beyond the barriers of light penetration: Strategies, perspectives and possibilities for photodynamic therapy
,” Theranostics
6
, 2458
–2487
(2016
).130.
T. M.
Baran
, H. W.
Choi
, M. J.
Flakus
, and A. K.
Sharma
, “Photodynamic therapy of deep tissue abscess cavities: Retrospective image-based feasibility study using Monte Carlo simulation
,” Med. Phys.
46
, 3259
–3267
(2019
).131.
C. L.
Campbell
, K.
Wood
, C. T. A.
Brown
, and H.
Moseley
, “Monte Carlo modelling of photodynamic therapy treatments comparing clustered three dimensional tumour structures with homogeneous tissue structures
,” Phys. Med. Biol.
61
, 4840
–4854
(2016
).132.
S.
Stolik
, J. A.
Delgado
, A.
Pérez
, and L.
Anasagasti
, “Measurement of the penetration depths of red and near infrared light in human ‘ex vivo’ tissues
,” J. Photochem. Photobiol. B Biol.
57
, 90
–93
(2000
).133.
T. A.
Henderson
and L. D.
Morries
, “Near-infrared photonic energy penetration: Can infrared phototherapy effectively reach the human brain?
,” Neuropsychiatr. Dis. Treat.
11
, 2191
–2208
(2015
).134.
J. R.
Starkey
, E. M.
Pascucci
, M. A.
Drobizhev
, A.
Elliott
, and A. K.
Rebane
, “Vascular targeting to the SST2 receptor improves the therapeutic response to near-IR two-photon activated PDT for deep-tissue cancer treatment
,” Biochim. Biophys. Acta - Gen. Subj.
1830
, 4594
–4603
(2013
).135.
L.
Song
et al., “Low-dose x-ray activation of W(VI)-doped persistent luminescence nanoparticles for deep-tissue photodynamic therapy
,” Adv. Funct. Mater.
28
, 1707496
(2018
).136.
N. M.
Idris
et al., “In vivo photodynamic therapy using upconversion nanoparticles as remote-controlled nanotransducers
,” Nat. Med.
18
, 1580
–1585
(2012
).137.
Y. R.
Kim
et al., “Bioluminescence-activated deep-tissue photodynamic therapy of cancer
,” Theranostics
5
, 805
–817
(2015
).138.
M. A.
Biel
, J. W.
Jones
, L.
Pedigo
, A.
Gibbs
, and N.
Loebel
, “The effect of antimicrobial photodynamic therapy on human ciliated respiratory mucosa
,” Laryngoscope
122
, 2628
–2631
(2012
).139.
A.
Ten Brinke
et al., “Chronic sinusitis in severe asthma is related to sputum eosinophilia
,” J. Allergy Clin. Immunol.
109
, 621
–626
(2002
).140.
G.
Kassab
et al., “Safety and delivery efficiency of a photodynamic treatment of the lungs using indocyanine green and extracorporeal near infra-red illumination
,” J. Biophotonics
13
, e202000176
(2020
).141.
D. J.
Minnich
, A. S.
Bryant
, A.
Dooley
, and R. J.
Cerfolio
, “Photodynamic laser therapy for lesions in the airway
,” Ann. Thorac. Surg.
89
, 1744
–1749
(2010
).142.
C. M.
Cassidy
et al., “Drug and light delivery strategies for photodynamic antimicrobial chemotherapy (PACT) of pulmonary pathogens: A pilot study
,” Photodiagnosis Photodyn. Ther.
8
, 1
–6
(2011
).143.
G.
Kassab
et al., “Nebulization as a tool for photosensitizer delivery to the respiratory tract
,” J. Biophotonics
12
, e201800189
(2019
).144.
A. C.
Zangirolami
, L. D.
Dias
, K. C.
Blanco
, C. S.
Vinagreiro
, and N. M.
Inada
, “Avoiding ventilator-associated pneumonia: Curcumin-functionalized endotracheal tube and photodynamic action
,” PNAS
117
, 22967
–22973
(2020
).145.
R.
Fekrazad
, “Photobiomodulation and antiviral photodynamic therapy as a possible novel approach in COVID-19 management
,” Photobiomodulation, Photomedicine, Laser Surg.
38
, 255
–257
(2020
).146.
L. D.
Dias
and V. S.
Bagnato
, “An update on clinical photodynamic therapy for fighting respiratory tract infections: A promising tool against COVID-19 and its co-infections
,” Laser Phys. Lett.
17
, 083001
(2020
).147.
Y.
Jin
et al., “Virology, epidemiology, pathogenesis, and control of COVID-19
,” Viruses
12
, 372
(2020
).148.
A.
Almeida
, M. A. F.
Faustino
, and M. G. P. M. S.
Neves
, “Antimicrobial photodynamic therapy in the control of COVID-19
,” Antibiotics
9
, 320
(2020
).149.
R.
Penjweini
, M. M.
Kim
, J. C.
Finlay
, and T. C.
Zhu
, “Investigating the impact of oxygen concentration and blood flow variation on photodynamic therapy
,” Proc. SPIE Int. Soc. Opt. Eng.
176
, 139
–148
(2017
).150.
Z.
Luo
et al., “Self-monitoring artificial red cells with sufficient oxygen supply for enhanced photodynamic therapy
,” Sci. Rep.
6
, 1
–11
(2016
).151.
S.
Darvekar
et al., “Selective killing of activated t cells by 5-aminolevulinic acid mediated photodynamic effect: Potential improvement of extracorporeal photopheresis
,” Cancers
12
, 377
(2020
).152.
S. R. G.
Fernandes
, R.
Fernandes
, B.
Sarmento
, P. M. R.
Pereira
, and J. P. C.
Tomé
, “Photoimmunoconjugates: Novel synthetic strategies to target and treat cancer by photodynamic therapy
,” Org. Biomol. Chem.
17
, 2579
–2593
(2019
).153.
H.
Yin
et al., “Evaluation of the effects of systemic photodynamic therapy in a rat model of acute myeloid leukemia
,” J. Photochem. Photobiol. B Biol.
153
, 13
–19
(2015
).154.
G.
Kim
and A.
Gaitas
, “Extracorporeal photo-immunotherapy for circulating tumor cells
,” PLoS One
10
, e0127219
(2015
).155.
Y. R.
Kim
, J. K.
Yoo
, C. W.
Jeong
, and J. W.
Choi
, “Selective killing of circulating tumor cells prevents metastasis and extends survival
,” J. Hematol. Oncol.
11
, 1
–4
(2018
).156.
D.
Schikora
and M.
Weber
, “Cancer metastases prevention by photodynamic in-vivo detection and destruction of circulating tumor cell clusters
,” Int. J. Clin. Oncol. Cancer Res.
4
, 38
–44
(2019
).157.
C. J.
Mycroft-West
et al., “The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 Receptor Binding Domain undergoes conformational change upon heparin binding
,” bioRxiv:2020.02.29.971093
1
–9
(2020
).© 2021 Author(s). Published under an exclusive license by AIP Publishing.
2021
Author(s)
You do not currently have access to this content.
